BiPER Therapeutics
First-In-Class Therapeutics Modulating ER Stress to Treat Poorly Sensitive Cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Debt | |
| Total Funding | 000k | ||
Related Content
BiPER Therapeutics is a preclinical stage biotech company founded in 2021, specializing in the development of innovative cancer treatments. The company focuses on creating "first-in-class" therapeutics, which means they are developing entirely new types of drugs that have never been used before. These drugs aim to treat cancers that are resistant to standard chemotherapy and immune-based therapies. This is a significant challenge in cancer treatment, as many patients do not respond well to existing options.
BiPER Therapeutics operates in the biotechnology and pharmaceutical market, specifically targeting oncology, which is the study and treatment of cancer. Their primary clients are likely to be healthcare providers, research institutions, and pharmaceutical companies looking for new cancer treatments.
The company's business model revolves around the discovery and development of small molecules that can selectively target cancer cells. Their lead compound, BPR001, targets a protein called BiP (Binding Immunoglobulin Protein), which plays a crucial role in cancer cell survival by modulating endoplasmic reticulum (ER) stress. ER stress is a condition in which the cell's protein-folding machinery is overwhelmed, leading to cell death. By modulating this stress, BiPER's drugs aim to selectively kill cancer cells while sparing healthy ones.
BiPER Therapeutics makes money through a combination of research grants, partnerships with larger pharmaceutical companies, and eventually, the commercialization of their drugs. As they are currently in the preclinical stage, their immediate revenue is likely coming from research funding and early-stage partnerships.
In summary, BiPER Therapeutics is a pioneering biotech company developing new cancer treatments that target the underlying mechanisms of cancer cell survival. Their innovative approach aims to fill a critical gap in the current cancer treatment landscape.
Keywords: Biotech, Oncology, Cancer Treatment, Drug Development, Small Molecules, ER Stress, BiP Protein, Preclinical Stage, Therapeutics, Innovation.